F
François Xavier Mahon
Researcher at University of Bordeaux
Publications - 40
Citations - 7064
François Xavier Mahon is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 23, co-authored 40 publications receiving 6497 citations. Previous affiliations of François Xavier Mahon include Hammersmith Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Moshe Talpaz,Richard T. Silver,Brian J. Druker,John M. Goldman,Carlo Gambacorti-Passerini,Francois Guilhot,Charles A. Schiffer,Thomas M. Fischer,Michael W. Deininger,Anne L. Lennard,Andreas Hochhaus,Oliver G. Ottmann,A Gratwohl,Michele Baccarani,Richard Stone,S Tura,François Xavier Mahon,Sofia Fernandes-Reese,Insa Gathmann,Renaud Capdeville,Hagop M. Kantarjian,Charles L. Sawyers +21 more
TL;DR: Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
Journal ArticleDOI
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
François Xavier Mahon,Michael W. Deininger,Beate Schultheis,Jerome Chabrol,Josy Reiffers,John M. Goldman,Junia V. Melo +6 more
TL;DR: It is concluded that BCR-ABL-positive cells can evade the inhibitory effect of STI571 by different mechanisms, such as Bcr-Abl overexpression, reduced intake mediated by Pgp, and, possibly, acquisition of compensatory mutations in genes other than BCR -ABL.
Journal ArticleDOI
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin,Alexandra Bazeos,François Xavier Mahon,Lina Eliasson,Dragana Milojkovic,Marco Bua,Jane F. Apperley,Richard Szydlo,Ritti Desai,Kasia Kozlowski,Christos Paliompeis,Victoria Latham,Letizia Foroni,Mathieu Molimard,Alistair Reid,Katy Rezvani,Hugues de Lavallade,Cristina Guallar,John M. Goldman,Jamshid S. Khorashad +19 more
TL;DR: In patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses.
Journal ArticleDOI
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Jane F. Apperley,Martine Gardembas,Junia V. Melo,Robin Russell-Jones,Barbara J. Bain,E. Joanna Baxter,Andrew Chase,Judith M. Chessells,Marie Colombat,Claire E. Dearden,Sandra Dimitrijevic,François Xavier Mahon,David Marin,Zariana Nikolova,Eduardo Olavarria,Sandra Silberman,Beate Schultheis,Nicholas C.P. Cross,John M. Goldman +18 more
TL;DR: Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB and all responses were durable at 9 to 12 months of follow-up.